In:
International Journal of Cancer, Wiley, Vol. 144, No. 10 ( 2019-05-15), p. 2605-2612
Abstract:
What's new? Patients with non‐small cell lung cancer (NSCLC) who develop liver metastases frequently suffer poor prognosis, despite treatment with otherwise highly effective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). In the effort to overcome this problem, the authors of this study examined patient outcomes following combined treatment with EGFR‐TKIs and local therapy. A significant improvement in progression‐free survival and overall survival was detected following administration of combined therapy in EGFR‐mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases. The findings suggest that combined local therapy and EGFR‐TKIs could help improve patient outcome in EGFR‐mutant NSCLC with liver metastasis.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2019
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8
Permalink